HIV Gut Dysbiosis and FMT: A Promising but Early Signal

Antiretroviral therapy can suppress HIV to undetectable levels, but viral control does not fully erase the higher rates of cardiovascular, metabolic, liver, neurocognitive, and frailty-related disease seen in people living with HIV. The leading explanation is not residual viral replication alone. It is persistent immune activation, and the gut may help maintain it.

A 2024 systematic review of 56 studies found a recurring pattern in treated HIV: depletion of bacterial families that produce short-chain fatty acids, especially Lachnospiraceae and Ruminococcaceae, alongside markers of gut-barrier injury and microbial translocation. A small double-blind fecal microbiota transplantation (FMT) trial then showed that this ecosystem can be shifted. It did not show that FMT prevents heart disease, improves cognition, or slows biological aging. Those are still open questions.

ART controls the virus, but the immune system may remain activated

For many people, modern ART turns HIV into a manageable chronic condition. Yet cardiovascular disease risk in virally suppressed people with HIV remains about twice as high as traditional risk factors alone would predict, according to the systematic review. The excess burden also extends to metabolic liver disease, fibrosis, neurocognitive decline, and frailty.

This does not prove that gut dysbiosis causes every one of those outcomes. HIV history, timing of treatment, co-infections, smoking, medication exposure, socioeconomic conditions, diet, and immune damage before ART all matter. Still, the gut has a plausible and measurable role in the remaining inflammatory burden.

A 2023 proteomic study found persistent abnormalities in inflammation- and immune-activation protein networks among virally suppressed people living with HIV, including signals that routine clinical laboratory tests may miss. That finding supports a central point: undetectable virus and fully normalized biology are different endpoints.

What HIV-associated dysbiosis looks like

The most consistent microbiome signature is lower abundance of Lachnospiraceae and Ruminococcaceae. These families include many microbes that help produce short-chain fatty acids (SCFAs), including butyrate. Butyrate helps support intestinal barrier function and influences immune regulation, including regulatory T-cell biology.

Lower diversity also tracks with evidence that bacterial products cross the intestinal barrier. In a 2022 cross-sectional study of people with HIV, lower gut microbial diversity was associated with higher circulating lipopolysaccharide (LPS) and soluble CD14 (sCD14), markers commonly used to assess microbial translocation and innate immune activation. An association cannot establish direction: barrier damage and inflammation can alter the microbiome, while an altered microbiome can also impair barrier function.

Several pathways could reinforce each other. Damage to the gut lining can allow LPS and other microbial products into circulation, where they can activate macrophages and endothelial cells. At the same time, loss of SCFA-producing microbes may reduce metabolites that help preserve the barrier and restrain immune activation. The systematic review also describes altered tryptophan metabolism, including impaired conversion toward indole-3-lactate, as another possible route to weaker epithelial repair.

The strongest clinical clue for the SCFA pathway comes from a 2023 prospective cohort study. Impaired microbiota-mediated SCFA production preceded subsequent morbidity and mortality in people with HIV. Because the study measured the microbial metabolic signal before outcomes occurred, it is more informative than a one-time correlation. It still cannot prove that restoring SCFA production will prevent those outcomes; interventions must answer that question.

The first placebo-controlled FMT trial changed diversity, with limited engraftment

That intervention test arrived in 2021. In the first double-blind, placebo-controlled FMT trial in virally suppressed people with HIV, Serrano-Villar and colleagues enrolled 30 participants with a CD4/CD8 ratio below 1 despite viral suppression. The modified intention-to-treat analysis included 14 participants assigned to oral donor-stool capsules and 15 assigned to placebo. Their median CD4/CD8 ratio was 0.64 (interquartile range 0.43 to 0.86), and median CD4 count was 582 cells/µL.

The investigators selected donors enriched in Lachnospiraceae and Ruminococcaceae, the families repeatedly depleted in HIV-associated dysbiosis. Participants received capsules over eight weeks. In the FMT group, observed taxonomic-unit richness increased from 250 at baseline to 287 at week 6. Placebo remained stable, and the between-group difference through week 7 was statistically significant (p=0.014). The richness signal remained statistically significant through week 48 (p=0.039).

That result matters, but it is a structural microbiome endpoint, not a patient outcome. It also did not mean that donor microbes had permanently taken over. Weighted UniFrac distance, a measure sensitive to shifts in taxon abundance and used here to assess donor-type engraftment, peaked around week 8. After week 8, it returned to baseline; the comparison was non-significant (p=0.995). In other words, the trial found a durable increase in richness but only small, transient quantitative donor engraftment.

This distinction is easy to blur and worth keeping sharp. A more diverse community might still change metabolism or inflammation through indirect effects, but the trial did not establish that mechanism. Nor did it establish durable gut-barrier repair: intestinal fatty acid-binding protein (IFABP), a marker of enterocyte injury, was a prespecified secondary endpoint, but its longer-term trajectory after treatment remains unresolved.

Why probiotics have not solved this problem

The FMT study also reviewed two 48-week randomized trials of probiotics or synbiotics in ART-treated people with HIV. Both found no difference from placebo in gut microbiota structure, systemic inflammation, or immune activation. A few added strains may not readily displace an established, dysbiotic ecosystem.

FMT offers a more complex intervention: an entire donor microbial community rather than a small set of organisms. That biological rationale does not make it ready for routine care. The first FMT study used oral capsules and a single treatment course, factors that may have limited delivery and persistence. Four FMT participants had recent antibiotic exposure, but that subgroup was far too small to determine whether antibiotic preconditioning changes engraftment.

Who may carry the greatest microbiome-related risk?

People whose immune markers remain skewed despite viral suppression may be an important group for future trials. A 2025 cross-sectional cohort study found that immune non-responders had different gut microbial communities and higher inflammatory cytokine burden than immune responders, with more severe depletion of Lachnospiraceae and Ruminococcaceae.

That makes immune non-responders a rational population to study, not proof that dysbiosis causes immune non-response. CD4/CD8 recovery also depends on factors such as CD4 nadir, timing of ART, thymic function, and co-infections. The FMT trial appropriately targeted participants with CD4/CD8 below 1, but it cannot tell us how common that phenotype is among all virally suppressed people with HIV.

ART helps the gut, but may not fully normalize it

The evidence does not support treating HIV-associated dysbiosis as fixed or universal. A 2021 study found partial preservation of gastrointestinal barrier function and microbiome composition in people with controlled HIV. A longitudinal 2022 study of people starting ART also found partial improvement in the microbiome-immunity axis alongside viral suppression and CD4 recovery.

These results fit a more precise conclusion: ART improves the gut environment for many people, but it often does not fully restore it. The residual abnormality may be clinically relevant, especially in people with persistent immune dysregulation.

The practical verdict

Gut health deserves serious clinical attention in virally suppressed people with HIV, particularly when CD4/CD8 remains below 1. The evidence links dysbiosis, microbial-translocation markers, persistent inflammation, and later health risks; the prospective SCFA study makes the metabolic pathway especially important. But most of the literature remains cross-sectional, and the systematic review identified frequent problems with control for diet, sex, and socioeconomic factors.

FMT has passed a narrow proof-of-concept test: in a 30-person placebo-controlled trial, it increased microbial richness through 48 weeks. It has not yet passed the test that matters most: fewer cardiovascular events, better metabolic health, less cognitive decline, or longer life. FMT should remain a research intervention for this purpose, guided by HIV and microbiome specialists rather than a do-it-yourself project. The mechanism is credible; the clinical prescription is not written yet.

For now, the useful conclusion is specific: suppressing HIV remains essential, and persistent gut-immune dysfunction is a plausible additional treatment target. Larger, longer trials must show whether changing the microbiome changes health outcomes.